- Home
- ELVN vs SSII Comparison
ELVN vs SSII Comparison
Compare ELVN & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SSII
- Stock Information
- Founded
- ELVN 2016
- SSII N/A
- Country
- ELVN United States
- SSII India
- Employees
- ELVN N/A
- SSII N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SSII
- Sector
- ELVN Health Care
- SSII
- Exchange
- ELVN Nasdaq
- SSII Nasdaq
- Market Cap
- ELVN 1.2B
- SSII 1.3B
- IPO Year
- ELVN 2020
- SSII N/A
- Fundamental
- Price
- ELVN $19.02
- SSII $5.30
- Analyst Decision
- ELVN Strong Buy
- SSII
- Analyst Count
- ELVN 5
- SSII 0
- Target Price
- ELVN $41.20
- SSII N/A
- AVG Volume (30 Days)
- ELVN 489.5K
- SSII 46.0K
- Earning Date
- ELVN 11-12-2025
- SSII 11-14-2025
- Dividend Yield
- ELVN N/A
- SSII N/A
- EPS Growth
- ELVN N/A
- SSII N/A
- EPS
- ELVN N/A
- SSII N/A
- Revenue
- ELVN N/A
- SSII $27,623,624.00
- Revenue This Year
- ELVN N/A
- SSII N/A
- Revenue Next Year
- ELVN $20.05
- SSII N/A
- P/E Ratio
- ELVN N/A
- SSII N/A
- Revenue Growth
- ELVN N/A
- SSII 134.89
- 52 Week Low
- ELVN $13.30
- SSII $2.48
- 52 Week High
- ELVN $30.03
- SSII $22.42
- Technical
- Relative Strength Index (RSI)
- ELVN 44.06
- SSII 35.73
- Support Level
- ELVN $18.01
- SSII $5.35
- Resistance Level
- ELVN $20.30
- SSII $7.00
- Average True Range (ATR)
- ELVN 1.11
- SSII 0.58
- MACD
- ELVN -0.16
- SSII -0.18
- Stochastic Oscillator
- ELVN 30.70
- SSII 0.00
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About SSII SS Innovations International Inc.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.